Wall Street brokerages predict that Illumina, Inc. (NASDAQ:ILMN) will announce earnings of $0.98 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Illumina’s earnings. The lowest EPS estimate is $0.92 and the highest is $1.06. Illumina posted earnings per share of $0.97 during the same quarter last year, which indicates a positive year-over-year growth rate of 1%. The business is scheduled to announce its next earnings report on Tuesday, November 7th.

On average, analysts expect that Illumina will report full-year earnings of $3.65 per share for the current fiscal year, with EPS estimates ranging from $3.62 to $3.70. For the next fiscal year, analysts forecast that the business will post earnings of $4.41 per share, with EPS estimates ranging from $4.15 to $4.78. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Illumina.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. The business had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. Illumina’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 earnings per share.

A number of research firms recently weighed in on ILMN. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 target price on the stock in a report on Tuesday, June 27th. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. J P Morgan Chase & Co restated an “overweight” rating and issued a $250.00 target price on shares of Illumina in a report on Wednesday, August 2nd. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price on the stock in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. Illumina currently has an average rating of “Hold” and an average price target of $177.01.

In related news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $91,221,235.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the transaction, the senior vice president now directly owns 10,646 shares of the company’s stock, valued at $1,854,959.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,705 shares of company stock valued at $27,344,118. 1.60% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Citizens Bank & Trust Co. boosted its holdings in Illumina by 0.4% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 12 shares during the period. Patten Group Inc. boosted its holdings in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the period. Puzo Michael J boosted its holdings in Illumina by 0.4% in the 2nd quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after purchasing an additional 25 shares during the period. Flagship Harbor Advisors LLC boosted its holdings in Illumina by 1.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after purchasing an additional 35 shares during the period. Finally, Eqis Capital Management Inc. boosted its holdings in Illumina by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after purchasing an additional 38 shares during the period. 93.34% of the stock is owned by institutional investors.

Illumina (NASDAQ ILMN) traded up 1.34% during mid-day trading on Thursday, hitting $210.20. The company had a trading volume of 757,035 shares. The firm has a market capitalization of $30.69 billion, a PE ratio of 42.17 and a beta of 0.81. The company’s 50 day moving average price is $191.38 and its 200-day moving average price is $178.42. Illumina has a 12-month low of $119.37 and a 12-month high of $211.27.

WARNING: “Illumina, Inc. (ILMN) Expected to Announce Earnings of $0.98 Per Share” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/07/illumina-inc-ilmn-expected-to-announce-earnings-of-0-98-per-share.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.